// App-Quantinova.ai

1095 : Phase Ib study of eribulin (ERB) and cyclophosphamide (CTX) in metastatic breast cancer (MBC).

Researchers

Presenter

  • Thach-Giao Truong

Principal Investigators

  • Michael Pelayo

  • Mark M. Moasser

  • Anne Reinert

  • Jimmy Hwang

  • John W. Park

  • Pamela N. Munster

  • Hope S. Rugo

Medical Centers

  • University of California, San Francisco, San Francisco, CA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CAUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Eribulin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01554371

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved